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Abstract
Background: Pharmacy service is an essential part of a healthcare system. The profession of pharmacy is well
recognized and is practiced to its full potential in developed countries however, it is underutilized in developing
countries such as Pakistan. The recognition of pharmacist’s role as healthcare professional is limited. This study
aimed to document pharmacists’ attitude towards their role in Pakistan’s healthcare system, their experience with
doctors and their perceptions towards involvement in medicines management.
Methods: A 4-month cross-sectional survey (Jan – Apr 18) was conducted targeting pharmacists practising in 26
tertiary care hospitals across Pakistan using a developed and validated questionnaire in both Urdu/English
languages. Chi square (χ2) test was used to report any associations between independent variables, i.e., education,
type of hospital and work experience and, dependent variables, i.e., pharmacists’ attitudes, experience, and
perception. A p-value of ≤0.01 with value of Cramer’s V ≥ 0.3 was considered cut-off for establishing statistical
significance. The study was approved by ethical committee and local hospital committees.
Results: Three hundred ninety-six questionnaires were returned out of 500, i.e., response rate = 87.9%. Most
participants (92.2%) interacted with doctors at least once daily. Most interactions were related to drug
availability inquiry (72.5%). Most pharmacists (91.4%) mentioned that pharmacy duties are mostly clinical in
nature. 93.4% of the respondents indicated that pharmacists are reliable source of information regarding
general medicines. Furthermore, 87.4% reasoned inadequate training for not being able to discuss issues of
clinical nature with doctors.
Conclusion: Pharmacists were willing to perform their duties and provide healthcare benefits to patients
however, they seemed sceptical of advanced clinical pharmacy roles such as intervening in prescriptions and
medication therapy, consultations and prescribing. There is a need to increase awareness regarding
pharmacist’s role. Therefore, it would be helpful if trainings and seminars are conducted on the importance of
clinical pharmacy to improve the pharmacy services in Pakistan’s healthcare system.
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Introduction
The profession of pharmacy has evolved from a product-
focused practice to a patient-oriented one [1]. In general,
the primary duties of the pharmacist include providing
drug information, medicines management, preparation
and dispensing of medicines, counselling of patients, and
formulating pharmaceutical care plan for patients [2].
Pharmaceutical care plan is an individualized service
provided by pharmacist that aims to improve the quality
of patient’s health [3, 4]. Pharmaceutical care involves a
collaborative relationship between the pharmacist and
the physicians to improve the health status of patients
[5]. It was envisioned that in future, pharmacists would
be greatly involved in clinical and administrative roles
and, their traditional roles of pill counting, packaging,
and dispensing would be performed by technicians and
trainees [6]. Literature suggests that pharmaceutical care
practice has a substantial positive effect on healthcare
and disease management in developed countries [7, 8].
However, the situation is different in developing countries
as the application of pharmaceutical care is hindered due to
time constraints, lack of standard reimbursement, less access
to patients’ records, poor communication among healthcare
professionals, insufficient number of qualified pharmacists
and absence of policies [8].
A pre-requisite to establishing effective pharmaceutical
care services would be the greater involvement of hos-
pital pharmacist as a member of allied health team with
increased interaction with other healthcare professionals.
Effective implementation of this service requires an un-
derstanding of a hospital pharmacist’s perception to-
wards the concept of pharmaceutical care, their role in
direct patient care and, the extent and level of inter-
action with other healthcare professionals [9]. The trad-
itional role of pharmacist has always been procurement
and inventory management of medicines along with en-
suring their safety and efficacy [10]. However, with the
introduction of ‘Pharmaceutical care’ concept by Hepler
and Strand during the 90s, the tradition role of pharma-
cist has transcended from medicine provider to a patient
care provider [11]. During the last few decades, pharma-
cists have practiced pharmaceutical care to improve pa-
tients’ treatment outcomes and maximize the benefits of
medication therapy to patients [5, 12].
According to the World Health Organization (WHO),
pharmacists are expected to advise allied health team re-
garding medication therapy management in patient care
and must have specialized knowledge and skills needed
to execute clinical pharmacy services [13, 14]. In
Pakistan, the health authorities have resolved to intro-
duce the pharmaceutical care services within the health-
care system to improve patient’s quality of life [15].
However, pharmaceutical care model is a novel concept
within pharmacy practice domain and is not clear to a
majority of health professionals and public [16]. Besides,
there are few pharmacists with knowledge of pharma-
ceutical care and clinical pharmacy services in healthcare
system. In addition, clinical guidelines are either not up-
dated or not available, that could highlight pharmacist’s
role in patient care. These are few notable determinants
of an enhanced clinical role of pharmacist in Pakistan’s
healthcare system [9, 17]. In addition, there is an acute
shortage of pharmacists in all healthcare sectors of the
country. Hospital pharmacists are involved to a greater
extent in traditional pharmacy services and administra-
tive activities. Furthermore, it has been observed that
pharmacy graduates in Pakistan preferred to join
pharmaceutical marketing and sales jobs [17–19].
Pharmacy curriculum in Pakistan has traditionally
been inclined towards drug manufacturing and dispens-
ing. During the last decade, the healthcare policymakers
envisioned a clinical role of pharmacist and since then,
the pharmacy curriculum has been modified to incorp-
orate courses related to clinical pharmacy practice [20–
22]. Moreover, the current pharmacy practice model in
Pakistan requires modifications concerning collaborative
practice supported by evidence and should have a clear
perspective in its application and conceptualisation [23,
24]. As this paradigm is novel in Pakistan, it requires
more planning for future perspectives suitable to the
country’s health policies. At the same time, it is impera-
tive to find out what pharmacists perceive about
pharmaceutical care service and their supposed engage-
ment with the other medical staff, to understand the de-
terminants that hinder their clinical role in Pakistani
healthcare settings.
Available literature highlights that interprofessional re-
lationship between doctors and pharmacists was not sat-
isfactory in the past. One of the reasons was education
and training of pharmacists [20–24]. Azhar and col-
leagues identified that the primary reasons for doctors’
low expectations with pharmacists were deficiency in
knowledge of therapeutics and inadequate clinical phar-
macy training [23]. In addition, Khan and colleagues
highlighted that workplace and experience of healthcare
professionals could influence views towards pharmacists
and their services [24]. Hence, having pharmacy educa-
tion that includes clinical courses is vital in shaping the
perception and expectations of pharmacists regarding
healthcare system of Pakistan.
In the past, adequate attention was not paid to update
pharmacy curriculum and thus, it could not contribute
significantly in achieving the healthcare objectives. The
4-year Bachelor of Pharmacy (BPharm) degree was
upgraded to a 5-year Doctor of Pharmacy (PharmD)
program by the Higher Education Commission (HEC) of
Pakistan in 2004. The course introduces an intensive
knowledge of clinical aspects of pharmacy. The updated
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program had courses that provided the knowledge of;
clinical and social aspects of pharmacy, such as drug
abuse, geriatric pharmacy, patient counselling, patient
compliance, research methods, and evidence-based
medicine, that have been largely ignored previously [9,
21, 22].
The health authorities of Pakistan should implement
pharmaceutical care practices in the health system of the
country, to promote safe use of medicines and improve
patients’ quality of life [23, 24]. The present study was
conducted to evaluate the acceptability of pharmacists as
a patient care provider, their interaction with the doctors
and, their perception about performing medicines man-
agement services. Thus, the study evaluated pharmacists’
viewpoint regarding their professional role in the health-
care system of Pakistan.
Methodology
Study objective
The primary objective of this study was to document at-
titude of pharmacists towards their role in Pakistan’s
healthcare system, their experience with doctors and
their perceptions towards involvement in medicines
management.
Study design, duration, and venues
This study was a cross-sectional survey that was con-
ducted for a period of 4 months, i.e., from January 2018
up to April 2018. Pakistan is located in South Asia and
hosts a population over 220 million. The healthcare sys-
tem of Pakistan consists of state funded and private sec-
tor healthcare facilities [25]. There are 968 state funded
hospitals across 8 administrative units of the country.
Since the state funded healthcare structure is inadequate
to fulfil healthcare needs of the population, most of
Pakistanis utilize private sector hospitals as well [21].
The study was conducted in 122 tertiry care hospitals in
27 cities of Pakistan that were in 6 administrative units
of the country (Fig. 1).
Target population and eligibility criteria
The target population was pharmacists working in hos-
pital settings in several cities of Pakistan. The eligibility
criteria of pharmacists were adopted from Naqvi et al.,
i.e., licensed pharmacists who were currently working in
healthcare settings of Pakistan for at least 1 year [14,
23]. All licensed pharmacists working in the pharma-
ceutical industry, academia and community pharmacies
were excluded. They were excluded from study since
they were not working in the healthcare settings and
may have different perceptions that may not be
representative.
Sampling strategy and sample size calculation
Data collection was conducted using convenience sam-
pling technique due to the unavailability of a database
that could highlight the exact number of pharmacists
practising in various hospitals across Pakistan. The study
sample size was estimated using an online sample size
calculator (RAOSOFT) [26]. As per the country’s
pharmaceutical data obtained from WHO 2010 report,
there were roughly 10,000 licensed pharmacists working
in all settings of Pakistan [25]. This figure was consid-
ered as target population. A 5% margin of error and 95%
confidence level was set. The required sample size was
370. A 2% drop-out rate (N = 8) was added to yield the
final number of 378 pharmacists.
Research instrument development and validation
The questionnaire was formulated for this study with
help from previous literature by a panel of experts in-
cluding two academicians and two clinical pharmacists
[7, 23, 24]. There were four sections in the questionnaire
that included demographic information about partici-
pants, the interactions of pharmacists with doctors, the
reasons for their interactions and, the perception of
pharmacists regarding their professional role in Pakistan’s
healthcare settings. Apart from demographic questions, it
included questions related to professional acceptance of
pharmacists in the healthcare system, pharmacists’ experi-
ence of working with doctors and, the involvement of
pharmacists in medicines management. The final ques-
tionnaire contained a total of 45 items and it took about
25min on an average to fill in the response. The options
for questions except for demographics were dichotomous,
i.e., in yes/no format. The questionnaire was formulated
in both English and Urdu languages. The English version
of questionnaire is available as a supplementary file (add-
itional file 1: Questionnaire).
The questionnaire was subjected to content validation
by a panel of experts that included three academicians,
two clinical pharmacists and three pharmacists. Each
member of the panel reviewed the questions and indi-
cated them as essential/non-essential. Content validation
was conducted using the methodology described by
Lawshe and Rungtusanatham [27, 28]. The content val-
idity index was reported at 0.81 which was greater than
the cut-off value 0.75 required for establishing validity
[27]. The reliability of questionnaire was estimated using
Cronbach alpha (α). The overall reliability for all items
(N = 45) was reported at 0.889. The intraclass correlation
coefficient was 0.889 (95% CI: 0.873–0.904). The reliabil-
ity for the section of professional acceptance of pharma-
cists in the healthcare system that contained 17 items
was 0.908. The intraclass correlation coefficient was
0.908 (95% CI: 0.894–0.920). Besides, the reliability for
the section of pharmacists’ experience of working with
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doctors that had 15 items, was 0.861 and intraclass cor-
relation coefficient was 0.861 (95% CI: 0.840–0.880).
Moreover, the reliability for the section of involvement
of pharmacists in medicines management that had 13
items, was 0.831 and intraclass correlation coefficient
was 0.830 (95% CI: 0.810–0.850). All were in acceptable
range [29, 30].
Data collection
The questionnaire was delivered as hardcopy by hand
and, were either completed at the same date or, collected
later as indicated by the respondent. Prior to handing
the questionnaire the participants were briefed about
study purpose.
Data analyses
The data were analysed using statistical software, (SPSS,
Chicago, IL, USA, version 24.0). The results were re-
ported, as sample count (N) and frequency (%). Cross
tabulation and chi square (χ2) test was applied to assess
the association between the independent variables (edu-
cation, type of hospital and experience of pharmacists)
and dependent variables (attitude, experiences of phar-
macists with doctors and involvement of pharmacists in
medicines management in the hospitals). The cut-off for
statistical significance was p-value ≤0.01 with value for
Cramer’s V ≥ 0.3. A p-value of ≤0.01 was set to reduce
the likelihood type 1 errors [31]. The Cramer’s V indi-
cated the strength of association and the value ranged
from 0 to 1 with latter indicating a strong association.
It was therefore selected as one of the cut-off criteria
[32].
Consent and ethics approval
All those who agreed to participate had to provide their
consent before data collection. The study was approved
by the Research Ethics Committee of the University
(Reference Number 00286). In addition, approval letters
from the local hospitals were also obtained before data
collection.
Results
Of total 500 pharmacists approached, 396 questionnaires
were completed giving a response rate of 79.2%, the re-
sults of which were then taken forward for analysis.
Most respondents were male (64.1%) and had Pharm. D
(Doctor of Pharmacy) degree (74.5%). Almost equal pro-
portions of respondents worked in state-funded (50.3%)
and private hospitals (49.7%) respectively. As per the job
titles of respondents, most respondents were working in
capacity of pharmacist (91.7%). Among all respondents,
almost 60% had experience of 5–10 years. Majority
(66.9%) were associated with in-patient pharmacy. Al-
most all (99.2%) respondents were registered with
Pakistan Pharmacy Council. The demographic informa-
tion data are tabulated in Table 1.
Upon eliciting opinion of pharmacists as to how they
describe the pharmacy job, most of them (N = 362,
91.4%) mentioned that pharmacy duties are mostly clin-
ical. However, a small number of pharmacists (N = 34,
8.6%) mentioned the duties as technical. In response to
the question of how they would describe pharmacy as an
occupation, most pharmacists (N = 351, 88.6%) men-
tioned it as a professional occupation while some phar-
macists (N = 20, 5.1%) believed it to be a business
profession. Similar number of pharmacists (N = 25, 6.3%)
mentioned pharmacy job as both professional and busi-
ness occupation.
Most participants (N = 365, 92.2%) reported that they
interacted with doctors daily while some pharmacists
(N = 18, 4.5%) reported that their interactions with doc-
tors were on a weekly basis. Few pharmacists (N = 13,
3.3%) reported that they rarely interacted with doctors
during their duty hours. In response to the question re-
garding most common reasons for these interactions,
most pharmacists (N = 287, 72.5%) mentioned drug
availability queries while some (N = 39, 9.8%) mentioned
queries regarding drug alternatives. A small number of
pharmacists (N = 29, 7.3%) mentioned queries related to
drug interactions while a similar number of participants
(N = 25, 6.3%) highlighted queries regarding dosage. Few
pharmacists (N = 16, 4%) mentioned queries related to
adverse drug reactions as one of the most common rea-
sons for interactions. The data regarding pharmacists’
attitude towards their role in the healthcare system and
their experience with doctors are tabulated in Tables 2
and 3. In addition, data related to the perception of
pharmacists about their involvement in medicines man-
agement are tabulated in Table 4. All items were cross
tabulated with three independent variables namely level
of education of doctors, the nature of hospitals, and
work experience of pharmacist.
Discussion
Pharmaceutical care is an integral part of pharmacy
practice in any healthcare setting, and its application
varies from one country to another depending upon
health regulations. The pharmaceutical care services are
advanced in developed countries and involve pharma-
cists in more clinical and patient-oriented roles. How-
ever, the involvement of pharmacists in pharmaceutical
care service and the extent of service coverage is limited
in developing countries such as Pakistan as there are less
pharmacists employed in hospitals. Their duties at most
times, are confined to drug dispensing, procurement,
and inventory management services, i.e., traditional
pharmacy services [33–39]. It has been mentioned earl-
ier that greater involvement of pharmacist in direct
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patient care and extensive interaction of pharmacists
with allied health members would set the platform for
improved pharmaceutical care services thereby benefit-
ing the patients. This could only be achieved when phar-
macists are involved in traditional duties to a lesser
extent. The traditional duties could be performed by
pharmacy technicians [10].
Most pharmacists mentioned that their role was clinic-
ally oriented and interacted with doctors on a daily basis.
This response was significantly associated with work-
place as pharmacists working in state funded hospitals
interacted more often with doctors. This occurrence
could be attributed to the change in healthcare policy
that envisioned such role for pharmacists. This occurrence
further highlights that Pakistani pharmacists now have a
better understanding of pharmaceutical care and consider
themselves as member of allied health team. Besides, they
regard their work as clinical and patient-oriented.
Most pharmacists agreed that their role and duties in
the primary health practice is of clinical nature. This indi-
cates that they were aware of their role as a healthcare
professional and, considered participation in drug pre-
scribing and therapeutic procedures as must. This finding
was linked to their education status as graduates with
PharmD degree or overseas degree in pharmacy, as op-
posed to BPharm, had better acceptance towards these
tasks. This finding could be attributed to the introduction
of PharmD degree with clinical pharmacy courses. It is in
line with the concept of enhancing pharmacists’ capabil-
ities and allowing them to contribute to the primary
healthcare system is being promoted, especially in devel-
oping countries [39, 40]. Henceforth, the introduction of
PharmD degree has led to a positive change in pharma-
cists working in Pakistani healthcare settings. Pharmacists
with a PharmD degree were observed to be better
acquainted with their clinical responsibilities. Moreover,
this finding is also in line with the role envisioned by the
WHO for pharmacists, that is, to serve in an advisory cap-
acity for other healthcare professionals in ensuring safe
and appropriate use of medicines [14].
The data pertaining to the experience of pharmacists
with the doctors highlighted that pharmacists were will-
ing to collaborate with doctors to discuss patients’ con-
dition and medication therapy. This occurrence was
linked to education status and workplace of pharmacists
as pharmacists with PharmD and working in state
funded healthcare facilities, were exercising these tasks
more often. However, the general perception of doctors
was negative. Available evidence indicates that doctors
perceived that pharmacists were incapable of providing
direct healthcare service to patient [38–40]. This nega-
tive perception is still prevalent among doctors despite
considering pharmacists as knowledgeable and experts
in counseling patients about drug dosage and its safe use
[24]. Besides, most patients in Pakistan are unaware that
they can consult pharmacists if they experience any drug
related problem during therapy [22, 24]. Due to this
negative perception among doctors and public
incognizance, the pharmacists have limited opportunities
to assume the role of a direct patient care provider and
mainly resort to practising managerial and administra-
tive tasks in public and private healthcare sectors.
It was observed that the perception of pharmacists
about their role in medicine management was quite
positive. The pharmacists believed that they were cap-
able of providing this service however, number of phar-
macists who had such expertise and training was low.
Table 1 Participants’ information (N = 396)
Characteristics N (%)
Gender
Male 254 (64.1%)
Female 142 (35.9%)
Professional Education
Bachelor of Pharmacy/ Master of Pharmacy 87 (22%)
Doctor of Pharmacy (Pharm.D) 295 (74.5%)
Overseas Qualification 14 (3.5%)
Place of Work
State Funded Hospital 199 (50.3%)
Private Hospital 197 (49.7%)
Current Job Title
Pharmacist 363 (91.7%)
Senior Pharmacist 26 (6.6%)
Chief Pharmacist 7 (1.8%)
Years of Experience
Less than 5 years 68 (17.2%)
5–10 years 236 (59.6%)
More than 10 years 92 (23.2%)
Area of Practice
Inpatient 265 (66.9%)
Outpatient 105 (26.5%)
Oncology pharmacy 26 (6.6%)
State of Practice
Sindh 143 (36.1%)
Punjab 175 (44.2%)
Baluchistan 9 (2.3%)
KPK 44 (11.1%)
Capital Territory 17 (4.3%)
AJK 8 (2.0%)
Are you registered with Pharmacy Council?
Yes 393 (99.2%)
In process 3 (0.8%)
KPK Khyber Pakhtunkhwa, AJK Azad Jammu and Kashmir
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This occurrence is logical given the previous pharmacy
curriculum that was focused on educating and training
pharmacy graduates in drug manufacturing and dispens-
ing. Thus, pharmacy graduates were mostly inclined to-
wards pharmaceutical manufacturing and medicines
dispensing. In India, a neighboring country, the situation
was similar to Pakistan’s pharmacy education scenario as
Indian pharmacy graduates and practicing pharmacists,
despite being in a large number, were educated in prep-
aration and dispensing of medicine only [37].
Pakistan’s pharmacy curriculum was revised in 2004;
the 4 year degree of Bachelor of Pharmacy (B.Pharm)
was upgraded to a full-time 5 year Doctor of Pharmacy
(Pharm.D) degree program. It was upgraded to
strengthen pharmacy graduates’ clinical knowledge and
practice [37–42]. Studies mentioned that on an average
2587 pharmacy students graduated from Pakistan’s phar-
macy schools every year. However, this number is not
sufficient to meet the demands of pharmacy profession
in country’s healthcare system [40]. According to avail-
able evidence, currently, 8102–10,000 pharmacists are
working in Pakistan, of which 55% are involved in the
production of pharmaceuticals, and only 15% are en-
gaged in community pharmacy [23, 40]. Moreover, in
addition to inadequate and untrained resource, doctors
were reluctant to engage the pharmacists in medicine
prescribing and related tasks [40, 41].
There is a need of understanding the role of pharma-
cists in Pakistani healthcare system and focus on their
training and utilization in the health sector. The issue of
under-recognized role could be addressed by attaching
pharmacy schools with hospitals similar to medical
schools so that pharmacy students may be able to prac-
tice their clinical knowledge in patient care and improve
their clinical skills [37–41]. Moreover, PharmD gradu-
ates must be given extensive duties in the clinical phar-
macy services so that they can progress and play their
role as healthcare professionals effectively [43].
Apart from traditional pharmacy roles, pharmacists
must assume the clinical role that contemporary health-
care service demands. Khan and colleagues highlighted
that most doctors in Pakistan do not consider pharma-
cist as an integral member of allied healthcare team [42,
43]. There is a need to increase their awareness regard-
ing the role pharmacists could play in Pakistan’s health-
care system. Evidence highlights that pharmacist’s
inclusion in disease management as member of allied
health team have improved patients’ treatment outcomes
[44]. Randomized controlled trials involving pharmacist
– driven pharmaceutical care model in Pakistani patients
with chronic illnesses such as diabetes, hypertension,
rheumatoid arthritis, etc., have shown significant im-
provements in treatment outcomes [44–47]. This evi-
dence base would improve pharmacists’ standing in
healthcare. In addition, allowing clinical pharmacists to
accompany allied health members during clinical rounds
and participation of pharmacists in continuous medical
education activities alongside other healthcare profes-
sionals would be beneficial for recognition of pharma-
cists as a clinical member of allied health team.
Additionally, spreading awareness about pharmacist’s
role through regional and national pharmacy societies
would also highlight pharmacists and their responsibil-
ities among health professionals and public.
Furthermore, pharmacists would have to increase pa-
tient awareness about their role. They would have to
perform their role as disease educator and counsellor.
The patients would not be able to understand the impact
a pharmacist could make in healthcare system unless the
pharmacists take initiative. Patient education and coun-
selling may not be clinically effective if the pharmacists
do not have pharmaceutical care skills [22]. Therefore, it
is essential to teach these skills to pharmacy students in
PharmD curriculum and provide them with opportun-
ities to practice during summer attachments or experi-
ential training [22, 39]. This would be helpful as the
pharmacy students would assume the role of pharma-
cists in future. There is a need to add provision of a
counselling room in regulations for healthcare settings
as this would provide opportunity for dissemination of
information regarding disease and therapy. Moreover,
such provision would enhance patient satisfaction and
improve the recognition of pharmacists as a patient care
provider [22, 39, 42, 43].
Limitations of the study
The results of this study may be interpreted with caution
as pharmacist from primary care hospitals, and commu-
nity pharmacies were not included. Therefore, the find-
ings of this study reflect the opinion of pharmacists
from clinical settings only. The views may differ among
pharmacist based on workplace. The study was a survey-
based research and involved close-ended questions.
Qualitative studies could investigate extensively and may
provide in-depth explanation of expectations as well as
experiences of pharmacists within the healthcare system
of Pakistan.
Conclusion
Pharmacists in Pakistan are willing to perform their du-
ties and provide direct patient care using their clinical
knowledge and expertise, pharmaceutical care skills and,
experience for medicines management. It was observed
that the updated curriculum improved their clinical
knowledge and health policy regulations have provided
more opportunities of pharmacists to collaborate with
doctors in patient care. However, they seemed sceptical
of performing advanced clinical pharmacy roles such as
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intervening in prescriptions and medication therapy,
consultations, prescribing, etc. This scepticism was
mainly due to a prevalent negative perception about
pharmacists’ clinical capabilities among most doctors.
It is essential to integrate pharmacists’ clinical rota-
tions with doctors to inculcate a professional relation-
ship. Moreover, it would be helpful if training and
seminars are conducted on the importance of clinical
pharmacy services in Pakistan’s healthcare system. Such
activities would provide an opportunity to recognize the
accomplishments as well as identify limitations of phar-
macists’ clinical role. Further studies are recommended
to explore the concerns of pharmacists regarding these
services so that they can be adequately addressed.
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